Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Prelude Therapeutics Announced The Presentation Of The First Interim Clinical Data From Its Ongoing Open-label, Dose-escalation Trial Of PRT2527, A Potent And Highly Selective CDK9 Inhibitor, As Monotherapy And In Combination With Zanubrutinib In Patients With Relapsed/Refractory Lymphoid Malignancies

Author: Benzinga Newsdesk | December 11, 2024 08:39am

Posted In: PRLD